Back to top
more

Glaukos (GKOS)

(Delayed Data from NYSE)

$133.89 USD

133.89
448,813

+1.30 (0.98%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $133.95 +0.06 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Fresenius Medical (FMS) Tops Earnings in Q4, View Upbeat

Fresenius Medical Care AG & Co. KGAA (FMS) reported adjusted earnings of 63 cents per American Depositary Share (ADS) in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 61 cents.

    Inovalon (INOV) Q4 Earnings In Line, Revenue Beat Estimates

    Inovalon Holdings, Inc. (INOV) reported fourth-quarter 2016 adjusted earnings of 2 cents per share, which came in line with the Zacks Consensus Estimate.

      Align Expands Internationally with Dental Couture Buyout

      Align Technology (ALGN) has recently announced the acquisition of Dubai, UAE and Nicosia, Cyprus-based distributor, G.L. Dental Couture Limited.

        Teleflex (TFX) Gains FDA Approval for TrapLiner Catheter

        Teleflex Incorporated (TFX) recently announced 510(k) clearance for its TrapLiner Catheter from the US FDA for a full fledged commercial launch in the country.

          Henry Schein Inks Agreement for Rijuven's CardioSleeve

          Henry Schein, Inc. (HSIC) recently signed an exclusive distribution agreement with patient care platform designer Rijuven Corp. to sell the latter's CardioSleeve device

            Wright Medical (WMGI) Posts Narrower-than-Expected Q4 Loss

            Wright Medical Group N.V. (WMGI) reported adjusted loss of 6 cents per share in the fourth quarter of 2016, narrower than loss of 8 cents reported in the year-ago quarter and the Zacks Consensus Estimate of a loss of 11 cents.

              DaVita (DVA) Ties Up with Cigna Arm, Expands in Los Angeles

              DaVita HealthCare Partners Inc. (DVA), a leading provider of dialysis services, announced that HealthCare Partners, a unit within its medical group, has entered into a strategic partnership with Cigna, a global health insurance service company.

                Henry Schein (HSIC) Tops Q4 Earnings, Reaffirms '17 View

                Henry Schein, Inc. (HSIC) reported adjusted earnings per share of $1.88 in the fourth quarter of 2016, up 12.6% year over year and surpassed the Zacks Consensus Estimate by 2.2%.

                  Ecolab's (ECL) Earnings, Revenues Miss Estimates in Q4

                  Ecolab Inc. (ECL) reported fourth-quarter 2016 adjusted earnings of $1.25 per share, which missed the Zacks Consensus Estimate of $1.27.

                    Medtronic (MDT) Beats on Q3 Earnings, Retains Sales View

                    Medtronic plc'S (MDT) third-quarter fiscal 2017 Adjusted earnings per share (EPS) came in at $1.12, a penny ahead of the Zacks Consensus Estimate.

                      Henry Schein to Acquire SAS to Strengthen Dental Offerings

                      Henry Schein Inc. (HSIC) announced its decision to acquire Southern Anesthesia + Surgical (SAS).

                        DENTSPLY (XRAY) Beats on Earnings in Q4, Misses Revenues

                        DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 67 cents in the fourth quarter of 2016, surpassing the Zacks Consensus Estimate by 2 cents.

                          Zacks.com featured highlights: Xcerra, Glaukos, Nova Measuring Instruments, Customers Bancorp and DNB Financial

                          Zacks.com featured highlights: Xcerra, Glaukos, Nova Measuring Instruments, Customers Bancorp and DNB Financial

                            Allscripts (MDRX) Q4 Earnings Miss Estimates, View Upbeat

                            Allscripts Healthcare Solutions, Inc.(MDRX) reported fourth-quarter 2016 earnings of 10 cents per share, which missed the Zacks Consensus Estimate by 2 cents.

                              DaVita (DVA) Earnings Beat Estimates, Revenues Lag in Q4

                              DaVita Inc. (DVA) reported fourth-quarter 2016 adjusted operating earnings of 98 cents per share that surpassed the Zacks Consensus Estimate of 91 cents.

                                GNC Holdings (GNC) Misses Q4 Earnings, Revenues Decline Y/Y

                                GNC Holdings Inc. (GNC) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 37 cents, down 88.1% and also missed the Zacks Consensus Estimate by 81.1%.

                                  Medtronic's Freezor Xtra Catheter Gains FDA Nod for AVNRT

                                  Medtronic plc (MDT) recently announced the receipt of U.S. FDA approval for its Freezor Xtra Cryoablation Catheter to treat patients with atrioventricular nodal re-entrant tachycardia.

                                    LabCorp (LH) Q4 Earnings and Revenues Beat, Offers View

                                    Laboratory Corporation of America Holdings (LH) or LabCorp reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.15, up 8.6% from the year-ago quarter.

                                      Chemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View

                                      Chemed Corp.'s (CHE) fourth-quarter 2016 adjusted earnings per share (EPS) was $2.02, missing the Zacks Consensus Estimate by 4.3%.

                                        Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss

                                        Omnicell, Inc. (OMCL) reported a breakeven in fourth-quarter 2016 earnings per share (EPS), a deterioration from the year-ago earnings of 5 cents.

                                          Masimo Gets CE Mark for RRp on MightySat Rx Pulse Oximeter

                                          Masimo Corporation (MASI) recently announced the receipt of CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter.

                                            CryoLife (CRY) Earnings Beat Estimates, Revenues Lag in Q4

                                            CryoLife, Inc. (CRY) posted fourth-quarter 2016 adjusted earnings per share of 12 cents, beating the Zacks Consensus Estimate of 8 cents.

                                              Cynosure (CYNO) to be Acquired by Hologic in $1.65B Deal

                                              Cynosure, Inc. (CYNO), announced that it has entered into a definitive merger agreement with Hologic, Inc. (HOLX).

                                                Express Scripts (ESRX) Earnings Top, Revenues Lag in Q4

                                                Express Scripts Holding Company (ESRX) posted fourth-quarter 2016 adjusted earnings per share of $1.88, beating the Zacks Consensus Estimate by a penny

                                                  Genomic Health (GHDX) Earnings Surpass Estimates in Q4

                                                  Genomic Health, Inc. (GHDX) reported fourth-quarter 2016 earnings per share of 4 cents, reflecting an improvement from the year-ago quarter's loss figure of 8 cents.